2007
DOI: 10.1111/j.1467-8519.2007.00559.x
|View full text |Cite
|
Sign up to set email alerts
|

A Critique of the Innovation Argument Against a National Health Program

Abstract: President Bush and his Council of Economic Advisors have claimed that the US shouldn't adopt a national health program because doing so would slow innovation in health care. Some have attacked this argument by challenging its moral claim that innovativeness is a good ground for choosing between health care systems. This reply is misguided. If we want to refute the argument from innovation, we have to undercut the premise that seems least controversial--the premise that our current system produces more innovati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2008
2008
2019
2019

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 9 publications
0
2
0
Order By: Relevance
“…If an expensive treatment is available on the market, citizens who need it and cannot pay for it (even after seeking charity) must choose whether to go without needed treatment or to steal the money 28 This empirical claim is speculative, but it is more plausible than the claim that any public health insurance program would reduce the quality of health care by reducing the rate of innovation. For a skeptical assessment of the latter claim, see Rajczi (2007). 29 One might raise the further worry that an egalitarian health care policy would be incompatible with any form of medical research that does not make experimental drugs available to all interested potential subjects.…”
Section: Leveling Down and Welfare Considerationsmentioning
confidence: 99%
“…If an expensive treatment is available on the market, citizens who need it and cannot pay for it (even after seeking charity) must choose whether to go without needed treatment or to steal the money 28 This empirical claim is speculative, but it is more plausible than the claim that any public health insurance program would reduce the quality of health care by reducing the rate of innovation. For a skeptical assessment of the latter claim, see Rajczi (2007). 29 One might raise the further worry that an egalitarian health care policy would be incompatible with any form of medical research that does not make experimental drugs available to all interested potential subjects.…”
Section: Leveling Down and Welfare Considerationsmentioning
confidence: 99%
“…The steady flow of innovative drugs has provided clinicians with a plethora of effective treatments. With healthcare providers continuing to struggle with rising costs, clinical effectiveness alone will no longer be the only criteria for evaluating a new treatment [9]. Economic evaluations of health care technologies typically utilize models to make assumptions and synthesize evidence from multiple sources in order to estimate costs and outcomes of new therapies [10].…”
mentioning
confidence: 99%